Takeda has launched two new dose strengths of Blopress Plus in Germany. These are fixed-dose combinations of 32mg candesartan. The maximum doses authorized in Europe are with 25mg and 12.5mg of hydrochlorothiazide.
The two new strengths are meant for the treatment of essential hypertension in patients whose blood pressure is not optimally controlled with 32mg candesartan or hydrochlorothiazide monotherapy.
Diuretic is launched for the first time in Europe after receiving marketing authorization from the local regulatory authority. The company has also got marketing authorization in Austria, Portugal and Spain. The company plans for further launches in other major European markets.
Erich Brunn, CEO, Takeda, said: “The new doses can provide additional blood pressure reduction to hypertensive patients who need more than monotherapy alone.”